Top Markets
Coin of the day
Chordia Therapeutics Inc. Chordia Therapeutics Inc.

Chordia Therapeutics Inc.

190A
Rank in Stocks #26484
Chordia Therapeutics Inc., a biotech company, engages in research and... Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Share Price
$0.53499835
Market Cap
$40.24M
Change (1 day)
2.50%
Change (1 year)
-58.07%
Country
JP
Trade Chordia Therapeutics Inc. (190A)

Category

Revenue for Chordia Therapeutics Inc. (190A)
Revenue in Aug 2026 TTM: 0
According to Chordia Therapeutics Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Chordia Therapeutics Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH
$2.23B -
US